Roman Spivak, MD
Pulmonary Disease · Ansonia, CTNPI 1780889493
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $121,125 of the $140,371 with a category attached, or 86.3%. GSK accounts for 93.5% of it on its own, with 36 other manufacturers making up the rest. Reporting peaked in 2023 at $53,654 and has fallen 92.4% since, to $4,079 in 2025. Among pulmonary disease clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 669 payments — averaging $209.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$131K
- AstraZeneca$3K
- Boehringer Ingelheim$761
- Medtronic$758
- Genentech USA, Inc.$463
- Mylan Specialty L.p.$391
- plus $4K from 31 others
What the payments were for
- Consulting fees$1,9501%
- Speaking & faculty fees$121,12586%
- Travel & lodging$2,8302%
- Food & beverage$14,09210%
- Education$3740%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 274 | $131,255 |
| AstraZeneca | 102 | $2,527 |
| Boehringer Ingelheim | 38 | $761 |
| Medtronic | 10 | $758 |
| Genentech USA, Inc. | 19 | $463 |
| Mylan Specialty L.p. | 20 | $391 |
| Regeneron Healthcare Solutions, Inc. | 19 | $371 |
| Sunovion Pharmaceuticals Inc. | 41 | $349 |
| Abbott | 2 | $303 |
| Takeda Pharmaceuticals U.S.A., Inc. | 15 | $284 |
| Sanofi | 13 | $279 |
| Johnson & Johnson(2 entities) | 10 | $274 |
| Baxter Healthcare | 10 | $231 |
| Electromed, Inc. | 17 | $203 |
| Sanofi-aventis U.S. LLC | 2 | $185 |
| Resmed Corp | 1 | $177 |
| Verona Pharma, Inc. | 11 | $160 |
| Novartis | 7 | $142 |
| Insmed, Inc. | 7 | $138 |
| Inspire Medical Systems, Inc. | 3 | $129 |
| Boston Scientific | 6 | $117 |
| Amgen | 6 | $112 |
| Advanced Respiratory, Inc | 4 | $97 |
| Merck | 5 | $97 |
| Lilly USA, LLC | 4 | $88 |
| Viatris Specialty LLC | 4 | $72 |
| Philips North America LLC | 4 | $71 |
| Haemonetics Corporation | 1 | $69 |
| Jazz Pharmaceuticals Inc. | 3 | $58 |
| Grifols USA, LLC | 1 | $44 |
| Circassia Inc. | 3 | $44 |
| Shire North American Group Inc | 2 | $43 |
| Pulmonx Corporation | 1 | $19 |
| Mallinckrodt Hospital Products Inc. | 1 | $19 |
| Actelion Pharmaceuticals US, Inc. | 1 | $18 |
| Vapotherm Inc | 1 | $14 |
| Eisai Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$61,378
- FASENRA$519
- BREZTRI$517
- ILLUMISITE$514
- TEZSPIRE$395
- AIRSUPRA$395
- CARDIOMEMS$303
- AirSense$177
- SYMBICORT$127
- AREXVY$108
How this compares
$140,371 in reported general payments places this provider in the 95th percentile of 255 pulmonary disease providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 702 | $641,395 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 74 | $70,076 |
| Breo ElliptaFluticasone/Vilanterol | 28 | $19,174 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 28 | $16,659 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 27 | $15,828 |
| Spiriva RespimatTiotropium Bromide | 11 | $12,852 |
| SymbicortBudesonide/Formoterol Fumarate | 30 | $12,502 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 388 | $7,554 |
| Ventolin HfaAlbuterol Sulfate | 17 | $1,270 |
| Prednisone | 168 | $819 |
| Montelukast Sodium | 124 | $763 |
| Methylprednisolone | 61 | $383 |
| Fluticasone Propionate | 29 | $302 |
| Moxifloxacin Hcl | 12 | $293 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 23 | $247 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $131,255 | $677,228758 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $2,527 | $82,578104 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat | $761 | $28,68038 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 255 pulmonary disease providers in Connecticut.
Other pulmonary disease in Ansonia
- Magdalen MaurielloAnsonia$8K
- Geoffrey ChuppNew Haven$1.2M
- Tapas BandyopadhyayWest Hartford$483K
- Raj ParikhHartford$386K
- Patrick TroyHartford$385K
- Michael ImevboreNew Haven$323K
- Jeffrey NascimentoHartford$213K
- Thinesh DahanayakeNorwich$192K
- Naftali KaminskiNew Haven$180K
- Daniel GerardiHartford$156K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.